Yvonne Baumer1, Sara McCurdy1, Martin Alcala2, Nehal Mehta3, Bog-Hieu Lee4, Mark H Ginsberg5, William A Boisvert6. 1. Center for Cardiovascular Research, John A. Burns School of Medicine, University of Hawaii, Honolulu, HI, United States. 2. Department of Chemistry and Biochemistry, Facultad de Farmacia, Universidad CEU San Pablo, Madrid, Spain. 3. Section of Inflammation and Cardiometabolic Diseases, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, United States. 4. Department of Food and Nutrition, School of Food Science and Technology, Chung-Ang University, Seoul, South Korea. Electronic address: lbheelb@cau.ac.kr. 5. Department of Medicine, University of California San Diego, La Jolla, CA, United States. 6. Center for Cardiovascular Research, John A. Burns School of Medicine, University of Hawaii, Honolulu, HI, United States; Kazan Federal University, Kazan, Russia. Electronic address: wab@hawaii.edu.
Abstract
BACKGROUND AND AIMS: Vascular smooth muscle cells (VSMC) migrate and proliferate to form a stabilizing fibrous cap that encapsulates atherosclerotic plaques. CD98 is a transmembrane protein made of two subunits, CD98 heavy chain (CD98hc) and one of six light chains, and is known to be involved in cell proliferation and survival. Because the influence of CD98hc on atherosclerosis development is unknown, our aim was to determine if CD98hc expressed on VSMC plays a role in shaping the morphology of atherosclerotic plaques by regulating VSMC function. METHODS: In addition to determining the role of CD98hc in VSMC proliferation and apoptosis, we utilized mice with SMC-specific deletion of CD98hc (CD98hcfl/flSM22αCre+) to determine the effects of CD98hc deficiency on VSMC function in atherosclerotic plaque. RESULTS: After culturing for 5 days in vitro, CD98hc-/- VSMC displayed dramatically reduced cell counts, reduced proliferation, as well as reduced migration compared to control VSMC. Analysis of aortic VSCM after 8 weeks of HFD showed a reduction in CD98hc-/- VSMC proliferation as well as increased apoptosis compared to controls. A long-term atherosclerosis study using SMC-CD98hc-/-/ldlr-/- mice was performed. Although total plaque area was unchanged, CD98hc-/- mice showed reduced presence of VSMC within the plaque (2.1 ± 0.4% vs. 4.3 ± 0.4% SM22α-positive area per plaque area, p < 0.05), decreased collagen content, as well as increased necrotic core area (25.8 ± 1.9% vs. 10.9 ± 1.6%, p < 0.05) compared to control ldlr-/- mice. CONCLUSIONS: We conclude that CD98hc is required for VSMC proliferation, and that its deficiency leads to significantly reduced presence of VSMC in the neointima. Thus, CD98hc expression in VSMC contributes to the formation of plaques that are morphologically more stable, and thereby protects against atherothrombosis.
BACKGROUND AND AIMS: Vascular smooth muscle cells (VSMC) migrate and proliferate to form a stabilizing fibrous cap that encapsulates atherosclerotic plaques. CD98 is a transmembrane protein made of two subunits, CD98 heavy chain (CD98hc) and one of six light chains, and is known to be involved in cell proliferation and survival. Because the influence of CD98hc on atherosclerosis development is unknown, our aim was to determine if CD98hc expressed on VSMC plays a role in shaping the morphology of atherosclerotic plaques by regulating VSMC function. METHODS: In addition to determining the role of CD98hc in VSMC proliferation and apoptosis, we utilized mice with SMC-specific deletion of CD98hc (CD98hcfl/flSM22αCre+) to determine the effects of CD98hc deficiency on VSMC function in atherosclerotic plaque. RESULTS: After culturing for 5 days in vitro, CD98hc-/- VSMC displayed dramatically reduced cell counts, reduced proliferation, as well as reduced migration compared to control VSMC. Analysis of aortic VSCM after 8 weeks of HFD showed a reduction in CD98hc-/- VSMC proliferation as well as increased apoptosis compared to controls. A long-term atherosclerosis study using SMC-CD98hc-/-/ldlr-/- mice was performed. Although total plaque area was unchanged, CD98hc-/- mice showed reduced presence of VSMC within the plaque (2.1 ± 0.4% vs. 4.3 ± 0.4% SM22α-positive area per plaque area, p < 0.05), decreased collagen content, as well as increased necrotic core area (25.8 ± 1.9% vs. 10.9 ± 1.6%, p < 0.05) compared to control ldlr-/- mice. CONCLUSIONS: We conclude that CD98hc is required for VSMC proliferation, and that its deficiency leads to significantly reduced presence of VSMC in the neointima. Thus, CD98hc expression in VSMC contributes to the formation of plaques that are morphologically more stable, and thereby protects against atherothrombosis.
Authors: Murray C H Clarke; Nichola Figg; Janet J Maguire; Anthony P Davenport; Martin Goddard; Trevor D Littlewood; Martin R Bennett Journal: Nat Med Date: 2006-08-06 Impact factor: 53.440
Authors: Sima Allahverdian; Ali Cyrus Chehroudi; Bruce M McManus; Thomas Abraham; Gordon A Francis Journal: Circulation Date: 2014-01-30 Impact factor: 29.690
Authors: Marina Poettler; Matthias Unseld; Kira Braemswig; Andrea Haitel; Christoph C Zielinski; Gerald W Prager Journal: Mol Cancer Date: 2013-12-21 Impact factor: 27.401
Authors: Yvonne Baumer; Qimin Ng; Gregory E Sanda; Amit K Dey; Heather L Teague; Alexander V Sorokin; Pradeep K Dagur; Joanna I Silverman; Charlotte L Harrington; Justin A Rodante; Shawn M Rose; Nevin J Varghese; Agastya D Belur; Aditya Goyal; Joel M Gelfand; Danielle A Springer; Christopher Ke Bleck; Crystal L Thomas; Zu-Xi Yu; Mårten Cg Winge; Howard S Kruth; M Peter Marinkovich; Aditya A Joshi; Martin P Playford; Nehal N Mehta Journal: JCI Insight Date: 2018-01-11
Authors: Yvonne Baumer; Sara McCurdy; Xueting Jin; Tina M Weatherby; Amit K Dey; Nehal N Mehta; Jonathan K Yap; Howard S Kruth; William A Boisvert Journal: Atherosclerosis Date: 2019-06-12 Impact factor: 5.162
Authors: Yvonne Baumer; Sara McCurdy; Tina M Weatherby; Nehal N Mehta; Stefan Halbherr; Pascal Halbherr; Noboru Yamazaki; William A Boisvert Journal: Nat Commun Date: 2017-10-24 Impact factor: 14.919